Colorectal and gastric cancer: Current and future therapeutic approaches. Part 3 - Future developments

episode

COR2ED - Oncology Medical Conversation not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Transrapid, Flugtaxis, Hyperloop – Warum es neuartige Verkehrstechnik so schwer hat 28 min · 22 Sep 2026 · Das Wissen | SWR

The Shadow Conflict_ Are We Already in World War III 4 min · 21 Sep 2026 · Conspiracy Theories Exploring The Unseen

Willson on Williams' injury significance, Mahomes' power and the Rams and Giants' showdown 27 min · 21 Sep 2026 · OverDrive

MNC: Brentford, Brighton & the silent treatment 56 min · 21 Sep 2026 · Football Daily

Evening Wire: The Press Sues Trump & NYC Preps for the UN 9.21.26 10 min · 21 Sep 2026 · Morning Wire

Full Show Podcast: 22 September 2026 1h 29m · 21 Sep 2026 · The Mike Hosking Breakfast

Report any issue

Source

Recorded06 Dec 2023

Publisherfeeds.castos.com ↗

Handlerec:7789318

Show notes

In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité University of Medicine, Germany) discuss the different therapeutic options available in colorectal and gastric cancer. In this third episode, the experts turn their focus to earlier stage disease and consider how lessons learnt in the treatment of metastatic disease can be applied in the neo adjuvant setting for colorectal cancer by discussing data from the FOXTROT and NICHE trials and the adjuvant setting for gastric cancer by discussing data from CheckMate 577. Finally, the experts consider new promising data on targeting KRAS compared to the MEK and the ERK inhibitors.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in